Spaarne Gasthuis Stichting — Clinical Trial Site

71 Registered trials

34 Currently recruiting

Organisation

Spaarne Gasthuis Stichting

Location

Hoofddorp, Netherlands

Identifier

ORG-100021671

Address

Spaarnepoort 1, 2134 TM, Netherlands

Departments

#2200 : oncology
#2200; oncology
2612:Cardiology
3708: Cardiology
Cardiology
Cardiology Department
Department of Oncology
Hemato-oncology
Hematology
Hematology / oncology
Intensive Care
Internal Medicine
Internal Medicine / Oncology
Internal Medicine/Oncology
Interne geneeskunde
Kindergeneeskunde
MDL
Medical Oncology
N/A
NA
Neurology
Nucleaire geneeskunde
Oncologie
oncology
Oncology-Hematology
Pediatrics
Pulmonary Medicine
Spaarne Gasthuis
Spaarne Gasthuis, Haarlem Zuid
Spaarne ziekenhuis, dept. Internal medicine
Surgery

Clinical trials at this site (71)

Search interface

DUTCH-WAIST Ended

2022-501392-81-00 Atrial fibrillation 6 2024-07-25
A phase 2 trial in stage II-IIIa urothelial cancer randomizing pre-operative nivolumab with or without relatlimab - TURANDORELA Ended

2023-507460-39-00 Adult patients with resectable muscle-invasive urotheli 10 2024-02-15
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended

2022-501024-20-00 ER+/HER2- Early Breast Cancer 5 2023-07-25
Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 … Ended

2023-507187-39-00 High-Risk Non-muscle-invasive Bladder Cancer 5 2023-03-23
A research study to see how well CagriSema helps people with excess body weight lose weight Ended

2023-506929-11-00 Overweight and obesity 5 2022-10-17
A trial to learn how well capivasertib with docetaxel works and how safe it is in people with metastatic castration-resistant prostate cance… Ended

2023-504996-26-00 Metastatic Castration Resistant Prostate Cancer (mCRPC) 5 2022-07-21
SEQUEL-Breast: a phase 2 study on the combination of alpelisib and fulvestrant after progression on previous therapy with fulvestrant in pat… Ended

2024-514965-20-00 Breast cancer 4 2022-06-02
Personalized dosing of ocrelizumab in MS Ended

2024-513193-22-00 Multiple Sclerosis 11 2022-03-16
A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended

2024-510735-21-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2021-11-26
Treatment combination of Durvalumab, Tremelimumab, Enfortumab Vedotin in patients with muscle invasive bladder cancer ineligible to cisplati… Ended

2023-507342-84-00 Bladder Cancer 5 2021-10-26
Safe shortening of antibiotic treatment duration for complicated Staphylococcus aureus bacteremia (SAFE-trial) Ended

2024-515398-90-01 Staphylococcus aureus bacteremia 5 2020-08-17
A Randomized Controlled Phase II Clinical Trial with Intradermal IMO-2125 (Tilsotolimod) in pT3-4 cN0M0 Melanoma (Intrim 1 study) Ended

2023-509461-20-00 pT3-4 cN0M0 Melanoma 4 2020-01-22
Image‐guided de‐escalation of neoadjuvant chemotherapy in HER2‐positive breast cancer: the TRAIN‐3 study Ended

2024-516205-23-00 Breast cancer 4 2019-04-09
Treatment with carfilzomib, lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smoldering Multi… Ended

2024-511334-12-00 Smoldering Multiple Myeloma 4 2018-11-19
Endocrine therapy plus CDK 4/6 inhibition in first- or second-line for hormone receptor positive advanced breast cancer - the SONIA study Ended

2024-516204-42-00 Breast cancer 5 2017-11-21
STAR-TREC: Can we Save the rectum by watchful waiting or TransAnal surgery following (chemo)Radiotherapy versus Total mesorectal excision fo… Ended

2024-516106-31-00 Early stage colorectal cancer 10 2017-06-16
Sustained treatment-free period in the course of a disease when symptoms become less severe in BCR-ABL+ chronic myeloid leukemia: a prospect… Ended

2023-510434-83-00 Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) 6 2016-10-17
Biomarker discovery randomized phase IIb trial with carboplatin-cyclophosphamide versus paclitaxel with or without atezolizumaB as first-lin… Ended

2024-516202-39-00 Metastatic breast cancer 4 2013-10-10
A Phase 4 Multicenter, Randomized, Open-label, Efficacy Assessor-blinded Study of Risankizumab Compared to Deucravacitinib for the Treatment… Ended

2023-509738-20-00 Plaque Psoriasis 6 2024-07-11
A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin … Ended

2024-513992-42-00 venous thromboembolism (VTE) in patients with gastroint 10 2022-09-13
A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on… Ended

2023-509569-19-00 venous thromboembolism (VTE) 10 2022-08-10
GIVE trial (Gazyvaro In combination with VEnetoclax in Elderly CLL) Ended

2024-511048-22-00 Chronic lymphocytic leukemia 4 2016-10-27
autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized Europea… Ended

2024-511235-10-00 Generalized mantle cell Lymphoma 5 2016-07-25